Skip to content

iDx Lung Health – Developing new tests for the early detection of lung cancer

Lung health checks in Wessex and Yorkshire: integrated biomarker studies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN39678730
Enrollment
7000
Registered
2021-02-03
Start date
2021-03-01
Completion date
Unknown
Last updated
2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early detection of lung cancer Cancer Malignant neoplasm of bronchus and lung

Interventions

This is a prospective cohort study for the collection of blood for autoantibody, protein and nucleic acid biomarkers, and nasal epithelium for transcriptomic analysis from individuals attending for lu

Sponsors

University Hospital Southampton NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Individuals undergoing a Lung Health Check 2. Ability to understand the study requirements and provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Deemed medically unfit for sample collection 2. Contraindication for study procedures or sampling

Design outcomes

Primary

MeasureTime frame
Measured using blood and nasal swab samples for biomarker analysis and clinical data routinely collected for the Lung Health Check (TLHC) at a single visit/timepoint when the patient has their CT scan: 1. Calculation of lung cancer risk stratification efficacy of one or any combination of biomarkers independent from or in combination with existing risk models (LLP/PLCOm2012) 2. Calculation of the alteration in diagnostic accuracy by the addition of one or more biomarkers to low dose CT scanning

Secondary

MeasureTime frame
Measured using blood and nasal swab samples for biomarker analysis and clinical data routinely collected for the Lung Health Check (TLHC) at a single visit/timepoint when the patient has their CT scan: 1. Cost-efficacy changes from the addition of one or more biomarkers to low dose CT scanning 2. Cost-benefit analysis of proposed optimised clinical algorithm

Countries

England, United Kingdom

Contacts

Public ContactDarran Ball
idxlung@soton.ac.uk+44 (0)23 8120 4128

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026